Publications by authors named "U Vitolo"

Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.

View Article and Find Full Text PDF
Article Synopsis
  • The IELSG37 trial investigated whether patients with primary mediastinal B-cell lymphoma (PMBCL) who have a complete metabolic response (CMR) after treatment can safely skip consolidation radiotherapy.
  • It was a randomized noninferiority study involving 545 patients, focusing on progression-free survival (PFS) over 30 months, with results showing high PFS rates of 96.2% for observation and 98.5% for radiotherapy.
  • The study concluded that avoiding irradiation does not negatively impact survival, highlighting positive outcomes for patients with CMR.
View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to assess the effectiveness of epcoritamab, a new bispecific antibody, for treating patients with advanced follicular lymphoma who have already undergone multiple previous therapies.
  • The research was part of the EPCORE NHL-1 trial, which took place at 88 sites across 15 countries and involved patients aged 18 and older with specific eligibility criteria, including having received at least two prior treatments.
  • Treatment involved subcutaneous injections of epcoritamab in cycles, with a tailored dosing strategy to minimize the risk of cytokine release syndrome, and the primary focus was on evaluating the overall response rate and safety measures related to cytokine release.
View Article and Find Full Text PDF

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [F]FDG PET (PET) in follicular lymphoma patients.

Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study.

View Article and Find Full Text PDF

Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis irradiation eliminates contralateral recurrences and reduces CNS relapses. The IELSG30 phase 2 study investigated feasibility and activity of an intensified IT and IV CNS prophylaxis.

View Article and Find Full Text PDF